The feasibility of using pathobiome strains as live biotherapeutic products for human use.

Authors :: Jin P
Lin X
Xu W
Li K
Zhao X
Guo S
Zhao Z
Jiang L
Liao F
Chang L
Wang M
Liu Y
Huang S
Chen Z
Ji F
Source :: IMeta [Imeta] 2024 May 26; Vol. 3 (3), pp. e202. Date of Electronic Publication: 2024 May 26 (Print Publication: 2024).
Publication Year :: 2024
Abstract: The evaluation of pathobiome strains should be conducted at the strain level, involving the identification of the functional genes, while considering the impact of ecological niche and drug interactions. The safety, efficacy, and quality management of live biotherapeutic products (LBPs), especially pathobiome strains, have certain peculiarities. Promising development methods include the recombinant LBP and active metabolites.<br />Competing Interests: The authors declare no conflicts of interest.<br /> (© 2024 The Authors. iMeta published by John Wiley & Sons Australia, Ltd on behalf of iMeta Science.)

Full Text Access

Tools